Baicalein (491-67-8) is an inhibitor of protein tyrosine kinase in leukemia (CEM) cells. Induces cell cycle arrest and apoptosis1. Originally reported as a selective inhibitor of 12-lipoxygenase, baicalein has since been shown to inhibit both 12-LO and 15-LO (IC50=0.64 μM for 12-LO and 1.6 μM for 15-LO)2. Baicalein displays antiinflammatory activity and inhibits adjuvant-induced arthritis. Also inhibits prolyl oligopeptidase (IC50=36 μM)3.
1) Lee et al. (2005), Baicalein induced cell cycle arrest and apoptosis in human lung squamous carcinoma CH27 cells; Anticancer Res., 25 959
2) Deschamps et al. (2006), Baicalein is a potent in vitro inhibitor against both reticulocyte 15-human and platelet 12-human lipoxygenases; Bioorg. Med. Chem., 14 4295
3) Tarrago et al. (2008), Baicalin, a prodrug able to reach the CNS, is a prolyl oligopeptidase inhibitor; Bioorg. Med. Chem., 16 7516